Abrégé

According to one embodiment of the present disclosure, disclosed is a method, performed by a computing device, for identifying a lesion location in a medical image. The method may comprise the steps of: acquiring a first medical image and a second medical image of a target object, each captured by different methods; acquiring, on the basis of the first medical image, by utilizing a first neural network model, a segmented brain image including brain segmentation information in which a brain is segmented into a plurality of regions; acquiring, on the basis of the second medical image, by utilizing a second neural network model, a lesion image including information about at least one lesion; and identifying, on the basis of a 3D lesion image generated from the second medical image and the lesion image, and the segmented brain image, a lesion region in which the at least one lesion is located from among the plurality of regions.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G06N 3/045 - Combinaisons de réseaux
• G06N 3/09 - Apprentissage supervisé
• G06T 7/00 - Analyse d'image

Abrégé

Embodiments of the present invention provide a method for providing medical information, the method comprising the steps of: acquiring a first medical image and a second medical image, which are obtained after a contrast agent is administered to a body tissue of a patient; extracting features related to the position of an eyeball from the first medical image and specifying the position of the eyeball on the basis of the features; tracking the center position of a crystalline lens by utilizing the specified position of the eyeball; and displaying the central position of the lens as a marker on the second medical image.

Classes IPC  ?

• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
• G06T 7/00 - Analyse d'image
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux

Abrégé

The present disclosure relates to a method and a device for generating a digital electrocardiogram signal on the basis of an electrocardiogram record. According to an embodiment of the present disclosure, a method for generating a digital electrocardiogram signal on the basis of an electrocardiogram record is provided, the method including the steps of: performing preprocess to extract first electrocardiogram information on the basis of a first electrocardiogram record; training an artificial intelligence segmentation model on the basis of the first electrocardiogram record and the first electrocardiogram information; segmenting a second electrocardiogram record into second electrocardiogram information by using the second electrocardiogram record as an input of the trained artificial intelligence segmentation model; and converting the segmented second electrocardiogram information into a digital electrocardiogram signal.

Classes IPC  ?

• A61B 5/333 - Appareils d’enregistrement spécialement adaptés à cet effet
• A61B 5/338 - Enregistrement par impression sur papier
• A61B 5/346 - Analyse des électrocardiogrammes
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention relates to a biomarker composition for screening a high-risk group of death after lung transplantation and use thereof. As a result of investigating the correlation between the expression of inflammatory cytokines and inflammation-related proteins as biomarkers before lung transplantation and clinical outcomes, a statistically significant difference was confirmed in abundance of various inflammatory cytokines and inflammation-related proteins between survivors and non-survivors, and a new prediction model using eight cytokines and inflammation-related proteins for survivors was found to exhibit a high AUC value. Therefore, the biomarker of the present invention is expected to be usefully employed as a biomarker for screening a high-risk group of death after lung transplantation.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Disclosed is a dressing fixation device. An embodiment of the present invention provides a dressing fixation device comprising: a cover part formed by mimicking the shape of a body part including an area to be treated; and a support part disposed along an edge of the cover part and having a thickness greater than the thickness of the cover part, wherein the cover part wraps around one side of the body part, in which the area to be treated is positioned, and the other side opposed to the one side and applies pressure to the area to be treated.

Classes IPC  ?

• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61F 13/02 - Bandages ou pansements adhésifs

Abrégé

The present invention relates to the formation of an organoid derived from colorectal cancer or sarcoma patient cells. In the present invention, it was confirmed that, when gelatin is used as an alternative material to a basement membrane extract (BME), compared to when a conventional BME is used, the formation of an organoid is more promoted, cancer indicator-related marker expression is more promoted, and structural stability is more improved, and it was also confirmed that metabolic activity is improved on the basis that oxygen consumption of the organoid increases. In addition, a medium for organoid formation of the present invention is more economical than a BME in terms of cost and organoid formation period. Limitations occurring in reproducing biological characteristics of a tumor in a colorectal cancer cell line and sarcoma patient-derived cells may be compensated for through a medium composition utilizing gelatin of the present invention, thereby enabling the provision of a physiologically similar model, and thus the present invention may be utilized in the future as a platform that is useful for preclinical research, diagnosis, and treatment evaluation.

Classes IPC  ?

• C12N 5/09 - Cellules tumorales

Abrégé

The present invention relates to: a support for culturing corneal cells, the support comprising graphene; and a use thereof. The support which is for culturing corneal cells and comprises graphene according to the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeleton remodeling and mitochondrial activation, and thus has the effect of being applicable to cell therapy products, graft materials in the field of regenerative medicine, and platforms for tissue engineering.

Classes IPC  ?

• C12N 5/079 - Cellules neurales
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

The present invention relates to the use of corneal cell-derived mitochondria for preventing or treating corneal damage or corneal endothelial cell diseases. Mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs), of the present invention, were confirmed to alleviate inflammatory responses of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, inhibit inflammatory responses, particularly inflammation caused by physical damage, upon delivery into xenogeneic primary corneal endothelial cells, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria having these effects can overcome the oncogenic limitations of conventional stem cell therapeutic agents, and are widely applicable and exhibit excellent cost efficiency due to their ease of production and fewer regulations.

Classes IPC  ?

• A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
• A61K 35/545 - Cellules souches embryonnairesCellules souches pluripotentesCellules souches pluripotentes induitesCellules souches non caractérisées
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention relates to a biomarker for prognostic prediction for sepsis, and use thereof. By evaluating the proteomic profile of sepsis patients by using SWATH-MS-based proteomics, PF4, CXCL7, ACTB, FINC, and TIMP1 were respectively identified as novel biomarkers for distinguishing the severity of sepsis and predicting outcomes of sepsis patients in the ICU, and, due to having excellent prognostic predictive performance for sepsis, are expected to be useful for prognostic predictive use and diagnostic use for sepsis, and the like.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The corneal endothelial transplantation device comprises: a balloon in which an expandable/contractible space is formed; and a catheter which provides a fluid for expanding the expandable/contractible space to the balloon. The balloon comprises: a thin-film part; and an expandable/contractible film part which has an edge part fixed to the edge part of the thin-film part such that the expandable/contractible space is formed between the thin-film part and the expandable/contractible film part, and on an outer surface of which a graft for transplantation to a transplantation site is disposed. When the graft is positioned at the transplantation site, the catheter expands the balloon such that the graft is brought into contact with the transplantation site.

Classes IPC  ?

• A61F 2/14 - Parties d'yeux, p. ex. cristallins ou implants de cornéeYeux artificiels
• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61M 25/10 - Cathéters à ballon

Abrégé

This organ fistula occlusion device comprises: a fistula occlusion film; and a catheter for moving the fistula occlusion film. The catheter comprises: a catheter tube; a guide member movably disposed inside the catheter tube so as to be insertable into and withdrawable from the catheter tube; and a deployment wire which is connected to an end of the guide member so as to be able to unfurl when discharged from the catheter tube, and to which the fistula occlusion film is attached. When the deployment wire is located at a fistula tissue site, the fistula occlusion film is separated from the deployment wire and attached to the fistula tissue site.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

The present invention relates to a composition and method capable of effectively predicting the therapeutic responsiveness of a subject to an antibody therapeutic agent for asthma, using blood EDN levels or urine EDN levels. In particular, the present invention can significantly increase the efficiency of predicting therapeutic responsiveness by configuring, as appropriate parameters, blood and urine EDN levels together with the number of blood eosinophils that were conventionally used to predict therapeutic responsiveness to antibody therapeutic agents for asthma. Therefore, the present invention can be usefully utilized for predicting the therapeutic responsiveness of a subject to various antibody therapeutic agents for asthma, such as mepolyizumab, resluzumab, and dupilumab.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present disclosure relates to an antibody binding to CD22, a bispecific antibody including the same, a chimeric antigen receptor, an antibody-drug conjugate, and uses thereof. According to one aspect, effective anticancer effects can be provided even for patients who are refractory to CD19-targeted therapies. Further, when using CD22 CAR NK cells or bispecific CD22/CD19 CAR NK cells, significantly enhanced reduction of cancer cells can be achieved.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to an exosome-derived miRNA biomarker isolated from duodenal pancreatic juice for the diagnosis of pancreatic cancer and uses thereof. More specifically, the present invention includes a miRNA biomarker capable of diagnosing pancreatic cancer, a composition for diagnosing pancreatic cancer using same, and a method for providing diagnostic information for pancreatic cancer using same. The miRNA presented in the present invention exhibits excellent diagnostic specificity and sensitivity for pancreatic cancer, and thus can be advantageously used not only for early diagnosis of pancreatic cancer through a non-invasive method, but also for predicting the progression of and therapeutic response for pancreatic cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

An electronic device for de-identifying personal information in clinical information text according to an embodiment comprises: a memory; and a processor for training a machine learning-based de-identification tag generation model on the basis of annotation data indicating a de-identification category for each token of training text and a training dataset including the training text, providing clinical information text for a patient input by medical personnel to the trained de-identification tag generation model, so as to output a de-identification category for each token of the clinical information text, and changing a token corresponding to personal information in the clinical information text into an expression indicating non-personal information on the basis of the output de-identification category.

Classes IPC  ?

• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
• G06F 40/284 - Analyse lexicale, p. ex. segmentation en unités ou cooccurrence
• G06F 40/169 - Annotation, p. ex. données de commentaires ou notes de bas de page
• G06F 40/117 - ÉtiquetageAnnotation Désignation de blocChoix des attributs
• G06F 40/151 - Transformation

Abrégé

Provided are exosome-derived microRNA biomarkers isolated from duodenal-pancreatic fluid for diagnosing pancreatic cancer, and uses thereof. Particularly, provided are a microRNA biomarker for diagnosing pancreatic cancer, a composition for diagnosing pancreatic cancer using the same, and a method for providing diagnostic information using the same. The microRNAs described herein demonstrate excellent diagnostic specificity and sensitivity for pancreatic cancer, and thus can be usefully employed in a non-invasive manner for early diagnosis of pancreatic cancer, as well as for predicting progression and treatment response of pancreatic cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

In one embodiment, a needle control device for an interventional pain procedure comprises an angle adjustment module and an insertion module, wherein the angle adjustment module includes: a base link; a first link rotatably connected to the base link; a second link rotatably connected to the base link; a third link rotatably connected to the first link; a fourth link rotatably connected to the second link, and rotatably connected to the third link; a first actuator for rotating the first link with respect to the base link; and a second actuator for rotating the second link with respect to the base link, and the insertion module can be fixedly connected to the third link.

Classes IPC  ?

• A61B 17/34 - TrocartsAiguilles à ponction
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
• A61B 34/35 - Robots chirurgicaux pour la téléchirurgie
• B25J 9/16 - Commandes à programme
• A61B 90/50 - Supports pour instruments chirurgicaux, p. ex. bras articulés
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

The present invention relates to a method for preparing pancreatic cancer organoids and a use of pancreatic cancer organoids prepared thereby. A method for preparing pancreatic cancer organoids using collagen and/or POSTN according to an aspect can be used to prepare pancreatic cancer organoids in which a patient's pancreatic cancer tissue and ECM environment thereof are well mimicked, and thus the prepared pancreatic cancer organoids can be used to effectively predict or evaluate the patient's pancreatic cancer prognosis or responsiveness to a specific drug treatment. A method for providing information for diagnosing or predicting the prognosis of pancreatic cancer according to one aspect can be used to effectively diagnose or predict the prognosis of pancreatic cancer by measuring the expression or expression level of POSTN in pancreatic tissue, pancreatic cancer tissue, the ECM thereof, etc.

Classes IPC  ?

• C12N 5/09 - Cellules tumorales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/575 -

Abrégé

In the present disclosure, in order to accurately classify stages of tumor, lymph node, and metastatic metastasis (TNM) in electronic medical record (EMR) data, a plurality of large language model (LLM) agents and a high-level prompting technique are utilized to analyze medical data and derive a consensus-based results according to majority. Specifically, disclosed are a cancer stage classification automation device and method in which a plurality of different LLM agents are independently applied to each of T, N and M such that error rate is reduced and the reliability of results is improved.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
• G06N 3/096 - Apprentissage par transfert
• G06F 16/3329 - Formulation de requêtes en langage naturel
• G06F 16/338 - Présentation des résultats des requêtes
• G06F 16/35 - PartitionnementClassement

Abrégé

This photodynamic therapy endoscope comprises: an endoscope body in which a working channel is formed; an optical fiber unit that is disposed in the working channel and emits light; and an endoscope cap inserted into an end of the endoscope body. The endoscope cap includes: a membrane coated with a photosensitive agent; and a cap part configured to be selectively connected to the front end of the endoscope body, wherein the membrane is positioned forward of the cap part.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux

Abrégé

The present invention relates to a novel Lactobacillus fermentum HEM20792 strain, a composition comprising the strain or a culture thereof for preventing or treating chronic obstructive pulmonary disease (COPD), and the like. The composition comprising a Lactobacillus fermentum HEM20792 strain (KCTC14066BP) as an active ingredient, according to the present invention, inhibits lung tissue damage and suppresses immune cells, and thus can prevent or treat COPD including emphysema. Therefore, it is expected that the present invention can be used to help cure pulmonary disease by eliminating a fundamental cause of COPD.

Classes IPC  ?

• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques

Abrégé

The present invention relates to universal immunomodulatory T cells comprising a chimeric antigen receptor and uses thereof and, specifically, to universal immunomodulatory T cells in which immunogenicity of cells is removed so that general T cells obtainable in sufficient numbers from healthy people can be applied to all organ transplant patients and in which Foxp3 and a chimeric antigen receptor are both introduced, and a use thereof.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A fusion protein may include a Cas protein and a bacterial toxin. Such a fusion protein, a polypeptide thereof, and/or a CRISPR-Cas system including the fusion protein may allow effective base editing. Due to the small size of the polypeptide, the polypeptide can facilitate delivery through vectors. In addition, when indels are accordingly induced, indel efficiency can significantly increase, and for indel induction, the size of nucleotides where indels are formed can also increase, whereby effective utilization can be made for gene knock-out.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

The present disclosure relates to an apparatus, a method, and a computer program for detecting cortical-cortical evoked potentials (CCEP) using transcranial magnetic stimulation (TMS). In particular, the apparatus comprises: a communication module for communicating with an external device; a memory storing at least one process for performing CCEP detection using the TMS; and a processor for performing CCEP detection using the TMS according to the process. The processor can be configured to: calculate noise intervals by collecting electroencephalogram (EEG) signals induced by TMS; cluster EEG channels excluding the calculated noise intervals; perform clustering EEG analysis on the basis of representative EEG signals of each cluster; perform individual EEG analysis on the basis of individual EEG signals within each of the clusters; and then detect CCEP signals on the basis of the clustering EEG analysis results and the individual EEG analysis results.

Classes IPC  ?

• A61B 5/383 - Stimuli somatosensoriels, p. ex. stimulation électrique
• A61B 5/372 - Analyse des électroencéphalogrammes
• A61N 2/00 - Magnétothérapie
• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

An IL10RA mutant protein according to one aspect of the present invention solves the issue of commercial IL10RA proteins being impossible to purify, and is a protein with improved purification efficiency. The IL10RA mutant protein is expressed at a similar level similar to the wild-type IL10RA protein, is normally located in the cell membrane, and exhibits the same level of anti-inflammatory signaling activity as the wild-type protein upon IL-10 stimulation, and thus can be effectively used as a protein replacement therapy for the treatment of inflammatory diseases.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a use of nicotinamide adenine dinucleotide (NAD) for preventing or treating olfactory disorders. The NAD increases the thickness of olfactory epithelial tissue and promotes the proliferation of olfactory stem cells and the differentiation thereof into olfactory neurons, and thus can effectively restore lost olfactory sense. Therefore, the NAD can be effectively used for preventing, ameliorating or treating olfactory disorders.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to novel antibodies or antigen-binding fragments thereof derived from plasma cells in cancer tissues of cancer patients, and uses thereof, and does not bind to normal cells and exhibits the activity of specifically binding to antigens of cancer cells. Therefore, the antibodies or antigen-binding fragments thereof can be effectively used in the diagnosis of cancer and, when bound to drugs such as an anticancer agent, the antibodies or antigen-binding fragments thereof can also be effectively used in the prevention or treatment of cancer and the like. In addition, the antibodies or antigen-binding fragments thereof are human antibodies or antigen-binding fragments thereof derived from plasma cells in the cancer tissues of cancer patients, and thus can be safely used in the diagnosis, prevention, or treatment of human breast cancer without having to undergo humanization in which specific amino acids of the variable region of the antibody are substituted in order to avoid or minimize an immune response in humans.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• A61P 35/00 - Agents anticancéreux
• C12Q 1/6869 - Méthodes de séquençage
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a method for preparing a radiopharmaceutical in which purification is performed by solid phase extraction (SPE) and to a cassette configured to perform the method in an automated synthesis module. By using a solid-phase extraction (SPE) process, the method for synthesizing an 18F-labeled radiopharmaceutical according to the present invention improves reproducibility and shortens synthesis time compared to a conventional HPLC process, thereby enabling production of an 18F-labeled radiopharmaceutical with high purity and high yield. By using a cassette configured to perform the synthesis method according to the present invention in an automated synthesis module, the 18F-labeled radiopharmaceutical can be conveniently synthesized. Accordingly, the method is expected to be advantageously applied to the production of 18F-labeled radiopharmaceuticals.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration

Abrégé

In the present invention, a deuterium-substituted FP-CIT linear precursor is developed in order to increase the linear stability of a precursor. When the deuterium-substituted FP-CIT linear precursor according to the present invention is dissolved in an organic solvent and stored, linearity is maintained well even at room temperature, and the same effect as a conventional radiopharmaceutical product [1866-[1866-[1866-[18F]FP-CIT enables visualization of dopamine transporter (DAT) distribution to be performed through improved image contrast, and has particularly high accuracy in diagnosing Parkinson's disease and related degenerative brain diseases, and thus can be effectively used.

Classes IPC  ?

• C07D 451/02 - Composés hétérocycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane, aza-9 bicyclo [3.3.1] nonane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane, p. ex. alcaloïdes du tropane ou du granatane, scopolamineLeurs acétals cycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane sans autre condensation, p. ex. tropaneLeurs acétals cycliques
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 51/04 - Composés organiques

Abrégé

The present invention relates to a composition for inducing differentiation of human induced pluripotent stem cells into insulin-producing cells, and a method for inducing differentiation into insulin-producing cells by using the composition.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/39 - PancréasÎlots de Langerhans
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

A method and a device for defending an artificial intelligence-based language model from an attack, according to one embodiment, may comprise the steps of: setting any one of a set of suffixes as an initial suffix; updating the set initial suffix by using an artificial intelligence-based training language model trained with a training data set including harmful instructions and safe responses corresponding to the harmful instructions, so as to determine an updated suffix; optimizing the updated suffix with a second gradient algorithm so as to determine a final defense suffix; and applying parameters of the training language model and the final defense suffix to the language model.

Classes IPC  ?

• G06N 3/094 - Apprentissage antagoniste
• G06N 3/084 - Rétropropagation, p. ex. suivant l’algorithme du gradient
• G06F 16/338 - Présentation des résultats des requêtes
• G06F 40/20 - Analyse du langage naturel
• G06F 16/3329 - Formulation de requêtes en langage naturel

Abrégé

The present invention relates to a method for providing information for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization. The gut microbiota of the present invention serves as a biomarker for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization in patients with liver cancer. The gut microbiota of the present invention can be utilized as a potential predictive factor for clinical outcomes of transarterial chemoembolization, can also be used as an adjunct therapeutic target for treatment of liver cancer patients, and enables prediction of survival rates of liver cancer patients who have undergone transarterial chemoembolization. Accordingly, the biomarker of the present invention is expected to be usefully applied as a marker for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization in patients with liver cancer.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12Q 1/6869 - Méthodes de séquençage

Abrégé

This cell sheet transplantation apparatus comprises a cell sheet and a catheter for moving the cell sheet. The catheter comprises: a catheter tube; a sheet pad to which the cell sheet is selectively attached; a guide member which is movably disposed inside the catheter tube to enter and exit the catheter tube, and which has an end portion to which the sheet pad is connected; and a control wire disposed inside the guide member to guide the movement of the sheet pad. The catheter further comprises: a catheter hub which is connected to the rear end of the catheter tube and in which the guide member can be moved; a pad adjustment unit which passes through the catheter hub and which is connected to the guide member; and a wire adjuster for guiding the movement of the control wire in the catheter hub.

Classes IPC  ?

• A61B 17/34 - TrocartsAiguilles à ponction
• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61F 2/06 - Vaisseaux sanguins
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents

Abrégé

Provided is a method of screening for an autophagy modulator. According to the screening method of an aspect, the autophagy modulator can be accurately screened with only a single cell. In addition, screening can be performed without using fluorescent labeling, and thus cytotoxicity and photobleaching that occur when fluorescent labeling analysis methods are used can be prevented, and the limitation of having to monitor only fluorescently labeled markers can be improved.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/41 - RéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present invention relates to a guide RNA targeting a specific mutation in an RS1 gene, a base editor comprising same, and use thereof and, specifically, to: a guide RNA targeting a c.422G>A (p.R141H) mutation found in the RS1 gene of patients with retinoschisis; a base editor comprising same; and use thereof.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 9/22 - Ribonucléases
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention relates to a humanized animal model incorporating a retinoschisis gene variant found in human patients and, specifically, to a humanized animal model carrying a c.422G>A (p.R141H) variant identified in the RS1 gene of human patients with retinoschisis, a use thereof, and the like.

Classes IPC  ?

• A01K 67/0278 - Vertébrés knock-in, p. ex. vertébrés humanisés
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

Biomarkers useful for detecting resistance to platinum-based chemotherapeutic agents (e.g., cisplatin) administered as pre-chemotherapy (NAC) for solid tumors (e.g., muscle-invasive bladder cancer (MIBC)). The biomarkers include glutathione-related genes, the expression levels of which can be used to determine the NAC resistance. The biomarkers are used in a method of determining chemotherapy resistance and in a method of treating a cancer in a subject.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61K 33/243 - PlatineSes composés
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle

Abrégé

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

Classes IPC  ?

• A61K 35/39 - PancréasÎlots de Langerhans
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

Provided are a dynamic image data-based object state prediction method and a computer device performing the same. The computing device includes a memory and at least one processor communicating with the memory. The processor obtains early dynamic image data corresponding to an early section after a medicine is injected into a learning object until a preset time point, learns a first prediction model for predicting first image data indicating anatomical information about the learning object corresponding to a time point earlier than a first section by using, as an input, early dynamic image data corresponding to the first section of the early section, and learns a second prediction model for predicting second image data indicating disease-specific information about the learning object corresponding to a reference time point after the early section by using, as an input, early dynamic image data corresponding to a second section of the early section.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

One aspect of the present invention relates to a method for preparing a high-purity corneal endothelial cell population. The method for preparing a high-purity corneal endothelial cell population according to one aspect can not only increase the efficiency of corneal endothelial cell differentiation from stem cells, but can also improve the function, survival rate, and purity of corneal endothelial cells directly differentiated from stem cells.

Classes IPC  ?

• C12N 5/079 - Cellules neurales

Abrégé

The present invention relates to a gene panel for predicting the responsiveness of renal cancer patients to radiotherapy. In the present invention, the responsiveness of patients to stereotactic body radiotherapy can be predicted with high accuracy by only biopsy of a small amount of tissue, thereby maximizing the efficiency of radiotherapy for patients with difficulty in surgery and at the same time, providing the advantage of preserving renal function.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs

Abrégé

This ligation structure comprises: an adhesive for ligating a blood vessel; and a clip (10) on which the adhesive is disposed, wherein the clip (10) comprises a biodegradable material. The adhesive comprises a hydrogel and maintains a ligated state of the blood vessel even after a degradation time, which is the time required for the clip (10) to biodegrade in a human body. The clip (10) comprises: a first binding portion on which the adhesive is disposed; a second binding portion on which the adhesive is disposed; and a connecting portion connecting the first binding portion and the second binding portion. When the blood vessel is in a ligated state by the adhesive disposed on the clip (10), the adhesive on the first binding portion and the adhesive on the second binding portion face each other.

Classes IPC  ?

• A61B 17/122 - Clamps ou pinces, p. ex. pour le cordon ombilical
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

A computing system for generating an SQL query executable in an OMOP CDM, according to an embodiment, may comprise a memory and a processor that: acquires selection criteria content indicating subject selection criteria of a selected clinical trial; acquires one or more split selection criteria; acquires refined selection criteria by providing a generation model with a second prompt indicating refinement of the one or more selection criteria; acquires extracted content by providing the generation model with a third prompt indicating content extraction for each of clinical information types; maps a concept identifier to the extracted content by providing the generation model with a fourth prompt indicating mapping of the concept identifier corresponding to a clinical term to the extracted content; acquires a merged SQL query by merging individual SQL queries for the refined selection criteria, which are acquired by providing the generation model with a fifth prompt indicating generation of an SQL query for selecting a subject of a clinical trial on the basis of the mapped extracted content; and acquires evaluation information about the merged SQL query by providing the generation model with a sixth prompt indicating evaluation of the merged SQL query.

Classes IPC  ?

• G06F 16/242 - Formulation des requêtes
• G06F 16/2453 - Optimisation des requêtes
• G06F 16/2455 - Exécution des requêtes
• G06F 16/84 - Mise en correspondanceConversion
• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G16H 70/00 - TIC spécialement adaptées au maniement ou au traitement de références médicales
• G06N 3/045 - Combinaisons de réseaux
• G06N 3/0475 - Réseaux génératifs
• G06N 3/096 - Apprentissage par transfert

Abrégé

The present invention relates to a composition for the prevention, alleviation, or treatment of fibrotic diseases, containing a Bacillus species strain, a Bacillus species strain spore, each expressing superoxide dismutase, and/or superoxide dismutase. When orally administered, the composition allows the polypeptide with superoxide dismutase activity to remove reactive oxygen species in vivo, thus being helpful for the prevention, improvement, or treatment of fibrotic diseases such as pulmonary fibrosis or hepatic fibrosis.

Classes IPC  ?

• A61K 38/44 - Oxydoréductases (1)
• A61K 35/74 - Bactéries
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention relates to an RNA-based method for predicting the occurrence of immune-related adverse events induced by cancer immunotherapy. As a result of analyzing various factors related to the occurrence of immune-related adverse events induced by cancer immunotherapy in the present invention, it was confirmed that a gene expression-based neutrophil score or immune cell profile is closely associated with the occurrence of immune-related adverse events. Therefore, the neutrophil score or immune cell profile is expected to be effectively used as a biomarker for predicting the occurrence of an immune-related adverse event induced by cancer immunotherapy or efficacy of cancer immunotherapy. In addition, the present invention relates to an RNA-based method for predicting efficacy of cancer immunotherapy. As a result of analyzing various factors related to efficacy to cancer immunotherapy in the present invention, it was confirmed that a gene expression-based tumor necrosis factor (TNF) score or immune cell profile is closely associated with efficacy. Therefore, the TNF score or immune cell profile is expected to be effectively used as a biomarker for predicting efficacy of cancer immunotherapy.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

A composition for detecting ICAM1 protein comprising the anti-ICAM1 antibody of the present invention can selectively detect the protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. The composition for detecting ICAM1 protein comprising an anti-ICAM1 antibody according to the present invention can selectively detect the corresponding protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. In particular, the anti-ICAM1 antibody contained in the composition specifically recognizes and binds to a structure in which sialic acid residues at the N-glycan terminal linked to the N130 asparagine residue of ICAM1 are reduced or deficient, that is, a hyposialylated glycosylation pattern. By targeting a glycosylation pattern appearing only in cancer cells, the antibody provides high therapeutic stability due to low non-specific binding to normal cells. Accordingly, the present invention offers an anti-ICAM1 antibody that precisely targets a cancer-specific glycan pattern and a novel immune-oncology therapeutic strategy based thereon, thereby overcoming limitations of existing anticancer agents and providing enhanced cancer treatment effects.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a novel compound and anticancer uses thereof and, more specifically, provides: a novel compound exhibiting inhibitory activity against HSP90, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition for preventing or treating cancer diseases comprising same; and a health functional food composition for preventing or improving cancer diseases comprising the compound.

Classes IPC  ?

• C07D 307/68 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/42 - Oxazoles
• A61P 35/00 - Agents anticancéreux
• C07D 261/18 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Abrégé

A system for text generation according to one embodiment may comprise one or more processors that select one summary candidate from among summary candidates obtained by providing, to a machine-learning-based summary generation model, summary-generation content instructing the machine-learning-based summary generation model to summarize a plan, obtain a weight by providing, to a machine-learning-based classification model, a prompt including query content containing a query inputted by a user and input content (220) including the plan and the selected summary candidate, obtain a query vector by providing the prompt to a machine-learning-based encoder model, generate one or more pieces of reference data by using pre-written plans and rule documents defining rules retrieved from a database on the basis of the query vector, calculate, for each token recognizable by a large language model (LLM), a first generation probability based on the prompt, a second generation probability based on the one or more pieces of reference data and the prompt, and a generation probability according to the weight by providing the one or more pieces of reference data and the prompt to the machine-learning-based generation model, and generate output text by sequentially selecting generation tokens from among a plurality of tokens on the basis of generation probabilities individually calculated for the plurality of tokens.

Classes IPC  ?

• G06F 16/34 - NavigationVisualisation à cet effet
• G06F 16/3329 - Formulation de requêtes en langage naturel
• G06F 16/338 - Présentation des résultats des requêtes
• G06F 16/334 - Exécution de requêtes
• G06F 16/31 - IndexationStructures de données à cet effetStructures de stockage
• G06F 16/35 - PartitionnementClassement
• G06F 40/284 - Analyse lexicale, p. ex. segmentation en unités ou cooccurrence
• G06F 18/2135 - Extraction de caractéristiques, p. ex. en transformant l'espace des caractéristiquesSynthétisationsMappages, p. ex. procédés de sous-espace basée sur des critères d'approximation, p. ex. analyse en composantes principales
• G06F 18/241 - Techniques de classification relatives au modèle de classification, p. ex. approches paramétriques ou non paramétriques

Abrégé

The present invention relates to a method for diagnosing whether anticancer therapy will exhibit responsiveness in a particular patient. The anticancer therapy may include chemotherapy or cancer immunotherapy. Specifically, whether anticancer therapy will exhibit responsiveness in a particular patient can be confirmed through a TCTP level in the plasma of the corresponding patient. In such an aspect, the present invention also relates to use of plasma TCTP as a biomarker indicative of responsiveness to anticancer therapy.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/535 - Production de composés immunochimiques marqués avec un marqueur enzymatique
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61K 33/243 - PlatineSes composés
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to an antibody that specifically binds to β2-microglobulin (β2m) and to uses thereof, in which the antibody specifically binds to free β2m protein that has dissociated from MHCI. The antibody or an antigen-binding fragment thereof binds to both the monomer and amyloid forms of β2m, and can detect the monomer and amyloid forms of free β2m in body fluids of dementia and kidney-disease animal models, and thus is useful as an antibody for diagnosing these diseases. In addition, the antibody or an antigen-binding fragment thereof protects damage to cognitive functions induced by β2m in normal mice, and exhibits: reduced amyloid beta and inflammation in the brain after intraperitoneal administration to a dementia mouse model; reduced renal fibrosis and biomarkers in a renal fibrotic disease animal model; and reduced liver fibrosis in a liver fibrotic disease animal model, and thus is useful for preventing and/or treating these diseases.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Genetic markers and a method for the diagnosis or prognosis of degenerative temporomandibular joint osteoarthritis. The method involved detection of a mutation of one or both of SMARCA2 and NOTCH1 or a mutant protein encoded thereby. The detection can be determined from a biological sample, such as saliva, which can be obtained by a non-invasive method. The method involves a random forest-based deep & wide model that is constructed by a machine learning (deep learning) method taken together with the genetic marker mutation information and has excellent diagnostic and predictive abilities with an accuracy of 97%.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G06N 20/00 - Apprentissage automatique
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

Abrégé

A blood flow volume quantification system based on a blood flow modeling includes: an image receiver configured to receive 4D flow magnetic resonance imaging (MRI) images and MRI images of a plurality of non-diseased individuals; a representative model generation unit configured to perform vessel segmentation based on the received MRI images and to designate a representative model from among the MRI images in which vessel segmentation has been performed, based on a predetermined criterion; an integrated model generation unit configured to register MRI images of other non-diseased individuals to the representative model to generate an integrated model; and a standard blood flow model generation unit configured to register the 4D flow MRI images to the integrated model to generate a standard blood flow model.

Classes IPC  ?

• A61B 5/026 - Mesure du débit sanguin
• G06T 7/00 - Analyse d'image
• G06T 7/10 - DécoupageDétection de bords
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux

Abrégé

Provided are a device, method and program for searching and training a preferred retinal locus of a patient with visual field damage. The method comprises the steps of: providing first stimulation to a patient by means of a stimulation providing device linked to the device; receiving, from the patient, a response with respect to the first stimulation by means of the stimulation providing device; if the response is correct, analyzing the movement of the patient's head corresponding to the first stimulation; specifying a preferred retinal locus on the basis of the analysis result; performing training associated with the patient's central fixation; and performing training associated with reinforcement of the patient's preferred retinal locus.

Classes IPC  ?

• A61B 3/024 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour la détermination du champ de vision, p. ex. périmètres
• A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre

Abrégé

Lacticaseibacillus rhamnosus Lacticaseibacillus rhamnosus HLL-002 strain; a probiotic composition comprising same; a health functional food composition comprising the composition; and a pharmaceutical composition for preventing or treating allergic diseases, comprising the strain.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61P 37/08 - Agents antiallergiques
• C12R 1/01 - Bactéries ou actinomycètes

Abrégé

The present disclosure relates to an infant and toddler motion analysis device and to a method therefor. The device comprises: a memory storing a process for analyzing motions of an infant or toddler; and a processor for executing the process, wherein the processor may determine whether a motion occurs in each of a plurality of body parts of the infant or toddler on the basis of acceleration data measured from sensors respectively attached to the plurality of body parts, and determine whether the motions of the infant or toddler are normal on the basis of the acceleration data measured for the plurality of body parts in which the motions are determined to have occurred.

Classes IPC  ?

• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

CandidaCandida sp. fungus; an antibacterial composition comprising same; and a pharmaceutical composition for preventing or treating diseases caused by pathogenic fungi. The ASO according to the present invention can be used as a gene therapeutic agent having a fungus-specific antibacterial effect by specifically inhibiting FKS1, FKS2, CHS3 and/or GWT1 genes, and can be a useful gene therapeutic agent that can be used in combination with or replace conventional antifungal agents for antifungal agent-resistant fungi or multidrug-resistant fungi.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A01N 63/60 - Acides nucléiques isolés
• A01P 3/00 - Fongicides
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 31/10 - Antifongiques

Abrégé

The present invention relates to: a method for differentiating stem cell-derived hepatocytes by using fasudil and gelatin; and the like. The method for differentiating stem cell-derived hepatocytes, according to the present invention, induces, by means of fasudil, the differentiation of stem cells into endoderm in an early stage of differentiation of stem cells into hepatocytes, inhibits lipid droplet formation through high-viscosity gelatin coating of a culture container, activates mitochondrial functions, up-regulates the expression of endoderm genes, and down-regulates the expression of ectoderm and mesoderm genes, thereby improving the efficiency of differentiation of stem cells into hepatoblasts. In addition, low-viscosity gelatin is added to the medium in a differentiation and maturation (late) stage so as to suppress the accumulation of lipid droplets, mitochondria are activated to improve the efficiency of differentiation of hepatoblasts into hepatocytes, and the function of differentiated hepatocytes is enhanced to improve the efficiency of differentiation of stem cells into hepatocytes. Therefore, hepatocytes obtained using the method are expected to be effectively used as a cell therapeutic agent, a transplant, and the like for treating liver diseases.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The present invention provides a painless lymph-targeted drug delivery patch comprising: a patch part having one side attached to a skin surface and having multiple through-holes through which a drug passes; multiple microneedle parts arranged along a pattern configured on one side of the patch part to inject the drug while being inserted into the skin; a drug chamber provided on the other side of the patch part to supply the drug to the microneedle parts through the through-holes; and an adsorption part provided on the other side of the patch part to selectively form negative pressure on the other side surface of the patch part or the skin surface.

Classes IPC  ?

• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61M 5/42 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour insensibiliser la peau, pour soulever la peau en vue de faciliter la piqûre ou pour localiser le point du corps où la piqûre doit être effectuée
• A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
• A61M 5/158 - Aiguilles

Abrégé

The present invention relates to a method for paper-based innovative nucleic acid extraction without centrifugation (PINE-CX) and a method for detecting nucleic acids in a sample using same. In the method according to an aspect, nucleic acids can be extracted and amplified from a sample with only a simple operation in a short time without centrifugation, and thus nucleic acid extraction and amplification efficiency is remarkably excellent. As a result, nucleic acids in a sample can be detected with high efficiency, and thus the method can be usefully used even in point-of-care testing (mPOCT) with limited resources.

Classes IPC  ?

• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

Provided is a method for tracking patient symptoms through a dialog system using a language model. The method comprises the steps of: extracting, through a router chain of a dialog system, at least one side effect list on the basis of a query message and a response message input by a patient with respect to the query message; routing to an inspection chain of the dialog system corresponding to the side effect list; and providing, through the inspection chain, a side effect grade on the basis of an additional response message input by the patient with respect to an additional query message based on the side effect list.

Classes IPC  ?

• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G06N 3/0475 - Réseaux génératifs
• G06N 3/096 - Apprentissage par transfert
• G06N 3/0895 - Apprentissage faiblement supervisé, p. ex. apprentissage semi-supervisé ou auto-supervisé
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

The present invention relates to an anti-apolipoprotein E4 (ApoE4) antibody and use thereof and, more specifically, to: an anti-ApoE4 antibody or an antigen-binding fragment thereof; a fusion in which the anti-ApoE4 antibody or an antigen-binding fragment thereof and one or more blood-brain barrier (BBB) receptor-binding peptides are bound; a method for preparing the fusion; and a composition for preventing or treating neurodegenerative diseases or metabolic diseases, comprising the anti-ApoE4 antibody or an antigen-binding fragment thereof, or the fusion.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/16 - Antiparkinsoniens
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a XIAP protein variant or a fusion protein comprising same, and use thereof. The XIAP protein variant according to one embodiment has an effect functionally equivalent to that of a wild-type XIAP protein, promotes ubiquitination of receptor-interacting serine/threonine-protein kinase 2 (RIP2) so as to activate NOD signaling, and has increased residual time and levels in cells relative to the wild-type XIAP protein, and thus can be effectively used in the treatment of inflammatory diseases, particularly diseases caused by NOD signaling defects.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

Disclosed is a method for analyzing a heart sound by an electronic device for measuring a preload of a general anesthesia surgery patient including splitting a heart sound and a breathing sound from heart-lung sound data of a patient obtained externally, specifying a breathing section from the split breathing sound, obtaining a heart sound envelope for obtaining a peak signal by converting a heart sound signal, obtaining a heart sound index from the heart sound envelope, and calculating an acoustic variability index (AVI) by analyzing the heart sound index.

Classes IPC  ?

• A61B 7/00 - Instruments d'auscultation
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/026 - Mesure du débit sanguin

Abrégé

The present invention relates to an apparatus and a method for refining bio-signal artifacts and, more specifically, comprises: a database in which bio-signals are stored; an extraction unit for extracting only clean signals from among the bio-signals; an augmentation unit for generating augmented artifacts by augmenting the clean signals; a storage unit for storing the clean signals and the augmented artifacts; a training unit for training a refining model by using a dataset generated on the basis of the augmented artifacts; and a refining unit for refining artifacts of the bio-signals by using the refining model, wherein previously unusable data is refined and converted into useful information, and thus the range of use of data can be widened, and both the quality and amount of clinical data can be improved by reducing data loss.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G06N 3/08 - Méthodes d'apprentissage

Abrégé

The present invention relates to a spiral epidural catheter. The spiral epidural catheter comprises: a catheter body having a passage formed therein and an inlet/outlet hole formed at a tip of a distal end part thereof, wherein a procedure tool is insertable into the passage, the distal end part faces a lesion target, the inlet/outlet hole communicates with the passage and allows the procedure tool to enter and exit therethrough, and the distal end part is tapered with a cross-sectional area gradually reduced toward the inlet/outlet hole; and a spiral part protruding or recessed in a spiral shape on an outer circumferential surface of the distal end part of the catheter body.

Classes IPC  ?

• A61B 17/34 - TrocartsAiguilles à ponction
• A61M 25/00 - CathétersSondes creuses

Abrégé

The present invention relates to a DNA methylation marker for diagnosing colon cancer and uses thereof and, more specifically, to: a combination of DNA methylation markers capable of determining the presence or absence of colon cancer; and uses thereof. The DNA methylation marker for diagnosing colon cancer, according to the present invention, can diagnose colon cancer with high accuracy by using only DNA methylation information of blood samples, without using colon cancer tissue samples, and thus can be effectively used for early diagnosis of colon cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme

Abrégé

The present invention relates to a method for providing information for the diagnosis and/or prognosis of aortic valve stenosis, and was arrived at by discovering that an increase in anti-citrullinated peptide antibody levels is associated with the onset and prognosis of aortic valve stenosis. The present inventors discovered that the accurate early diagnosis of aortic valve stenosis is possible through measuring anti-citrullinated peptide antibody levels, and the degree of aortic valve deformity, severity, and probability of complications such as hypertension, rheumatoid arthritis, and interstitial lung disease can be predicted, and thus the anti-citrullinated peptide antibody is expected to be used as a biomarker for more effective diagnosis, prognosis, and treatment of aortic valve stenosis.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed is an articulated device including a base member, a shuttle member disposed in the base member to be movable to any one of a first position or a second position disposed to be spaced apart from the first position on the base member, and a unit joint provided between the base member and the shuttle member to be movable in the base member together with the shuttle member, and including an elastic member that generates an elastic force to the base member and the shuttle member.

Classes IPC  ?

• B25J 9/06 - Manipulateurs à commande programmée caractérisés par des bras à articulations multiples
• A61B 34/30 - Robots chirurgicaux
• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs

Abrégé

The present invention relates to a pain evaluation model generation method. One embodiment of the present invention provides a pain evaluation model generation method comprising the steps of: acquiring a photoplethysmogram signal of a subject; selecting at least one input index from the acquired photoplethysmogram signal; and generating a pain evaluation model capable of evaluating the pain of the subject by performing machine learning using the selected input index as input data, wherein the acquired photoplethysmogram includes a first photoplethysmogram acquired at a first time point at which the subject is anesthetized and a second photoplethysmogram acquired at a second time point at which the subject recovers from the anesthesia after the first time point.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G06N 20/20 - Techniques d’ensemble en apprentissage automatique

Abrégé

The present invention relates to a pyrrolopyrimidinone carboxamide compound represented by Chemical Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for treating cancer, comprising the same as an active ingredient. Specifically, the compound increases plasma stability so that, until the compound reaches cancer cells, the structure thereof is maintained, and thus the compound exhibits anticancer effects greater than those of existing compounds.

Classes IPC  ?

• C07H 19/14 - Radicaux pyrrolo-pyrimidine
• A61K 31/7064 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées
• A61P 35/00 - Agents anticancéreux

Abrégé

A fusion protein, according to one aspect, enables effective base editing within organelles, and provides an effect of enabling genetic base editing of both cell nucleus and organelles by using a single fusion protein.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

This microneedle patch comprises: a sheet; a biodegradable needle, which is detachably connected to the sheet, extends in one direction from the sheet, and has a drug accommodation part formed therein; and a photosensitizer disposed to encompass the outer surface of the biodegradable needle. The photosensitizer is disposed to be coated on the outer surface of the biodegradable needle, and the biodegradable needle is elongated beyond the thickness of the sheet.

Classes IPC  ?

• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux

Abrégé

The present invention relates to a bacterial toxin variant and use thereof. According to an aspect, a variant, a fusion protein, a polypeptide thereof, and a base editing system including same facilitate binding with Cas proteins because the polypeptide size is small, and compared to an existing base editing system using Ssda proteins, base editing efficacy is significantly improved, enabling more effective base editing, and base editing is also possible in cell organelles.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

Disclosed is an operating method of a medical image processing device using augmented reality (AR) including obtaining, from a first external device, a first image including blood vessel information and bone tissue information according to tomography, obtaining, from a second external device, a second image including a facial structure and a facial curve according to 3D imaging, extracting a facial feature point from facial unique information including the blood vessel information, the bone tissue information, the facial structure, and the facial curve, registering the first image to the second image based on the facial feature point, generating a composite image by performing 3D-modeling on the first image registered with the second image, projecting the composite image onto a face of a patient, and displaying, on a projected image, a first layer corresponding to the blood vessel information and a second layer including the bone tissue information.

Classes IPC  ?

• G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés basés sur les caractéristiques
• A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
• G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
• G06T 19/00 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie
• G06V 40/16 - Visages humains, p. ex. parties du visage, croquis ou expressions

Abrégé

The present disclosure relates to an apparatus and method for early evaluation of lymphedema occurrence by determining the regularity of lymphatic contractions, the apparatus comprising a memory for storing at least one instruction for early evaluation of lymphedema occurrence, and a processor for performing operations according to the instruction, wherein the processor: monitors, by using indocyanine green lymphography, the occurrence of lymphedema in an animal model in which lymph nodes have been resected to disconnect lymphatic circulation in an upper limb from the proximal region; measures lymphatic contraction signals at a distal site to detect the onset of and changes in lymphatic circulation disorder; compares the measured lymphatic contraction signals with the lymphatic contraction signals from a normal site; monitors changes in the lymphatic contraction signals at the distal site; and determines the presence of lymphedema on the basis of the monitoring results.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

Disclosed is a microneedle drug delivery stent capable of locally delivering a drug into a luminal organ. The microneedle drug delivery stent comprises: a coating stent; and a microneedle formed in the coating stent to carry a drug, wherein the coating stent may have a coating groove in which the microneedle is formed.

Classes IPC  ?

• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61F 2/848 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents avec des moyens de fixation à la paroi du vaisseau, p. ex. des barbes
• A61F 2/90 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles
• A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires

Abrégé

The present disclosure relates to an apparatus and method for detecting a lymphatic contraction signal in real time, wherein the apparatus includes: a contrast medium injection module for injecting a fluorescent material including a lymphatic contrast medium into a subcutaneous interstitial fluid through a drug delivery system; a conversion module that obtains an optical signal by tracking the fluorescent material and converts the obtained optical signal into an electrical signal; a signal processing module that sets the electrical signal as a target signal and removes noise from the set target signal; an analysis module for analyzing the target signal from which the noise has been removed; and an output module that visualizes a result of analyzing the target signal and transmits same to an output device.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A cage-type electric pulse catheter comprises: a handle; a catheter tube connected to the handle; a catheter rod movably disposed inside the catheter tube to allow the end thereof to be able to enter and exit from the catheter tube; a rod tip coupled to the end of the catheter rod; a leaflet member which is disposed on an outer surface side of the catheter rod and can be selectively unfolded in the outer diameter direction of the catheter rod when the catheter rod moves in the longitudinal direction; and a leaflet electrode disposed on the leaflet member.

Classes IPC  ?

• A61B 18/14 - Sondes ou électrodes à cet effet
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci

Abrégé

This stent comprises: a main body part including a drainage passage and an installation passage; and a removal string inserted into and fastened to the installation passage. The installation passage extends inside the main body part in the front-rear direction and passes through the main body part, and the removal string is inserted into the installation passage so as to extend frontward from the front end of the installation passage and extend rearward from the rear end of the installation passage. A protrusion part is further included, which protrudes toward the drainage passage from an inner surface of the main body part that forms the drainage passage and extends along the inner surface in the front-rear direction, wherein the installation passage is formed to span the main body part and the protrusion part.

Classes IPC  ?

• A61F 2/95 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes
• A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents

Abrégé

This rhinitis catheter comprises: a main body for providing a refrigerant container for accommodating a refrigerant, and a mounting space in which the refrigerant container can be accommodated; a valve assembly for selectively discharging the refrigerant from the refrigerant container; a switch unit capable of controlling the operation of the valve assembly; and a sheath unit for guiding, to the nasal cavity, the refrigerant discharged from the refrigerant container. The valve assembly includes: a valve block which is disposed in the mounting space so as to enable communication with the refrigerant container, and which provides a block channel for guiding the discharge of the refrigerant; a fixing ring coupled to the block channel; a supporter which is coupled to the fixing ring and which has a supporter flow path formed therein; and an opening/closing member which is disposed in the supporter flow path so as to be liftable/lowerable, and which can selectively block the block channel by means of the operation of the switch unit.

Classes IPC  ?

• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
• A61M 39/22 - Soupapes ou agencement de soupapes

Abrégé

The present invention relates to a stem cell spheroid therapeutic agent for preventing or treating a temporomandibular joint disease and a method for producing same. Specifically, the stem cell spheroid therapeutic agent comprises, as an active ingredient, stem cell spheroids overexpressing at least one gene selected from the group consisting of IDO and FGF2, and when used, prevents cartilage loss in temporomandibular joints and promotes bone regeneration, and has an anti-inflammatory effect, and thus can be effectively used for the fundamental prevention and treatment of temporomandibular arthritis.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses

Abrégé

The present disclosure relates to a visual perception learning-based apparatus and method for providing stereovision training, the apparatus including: a display module; a memory storing at least one stereovision training-based process for improving strabismus; and a processor that generates first stimulus plate for orthophoria among the both eyes of a trainee and a second stimulus plate for strabismus among the both eyes, and provides the stereovision training by adjusting of a difficulty level of a first stimulus among a plurality of stimuli included in each of the first stimulus plate and the second stimulus plate, wherein the difficulty level can be adjusted through at least one of a three-dimensional effect setting of the stimulus, a shape setting of the stimulus, an interval setting of the stimulus, an edge setting of the stimulus, and a background color setting of the stimulus.

Classes IPC  ?

• A61H 5/00 - Appareils pour l'exercice des yeux
• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
• G02B 27/01 - Dispositifs d'affichage "tête haute"
• A61F 9/02 - Lunettes protectrices

Abrégé

The present invention relates to a pharmaceutical composition for preventing cancer comprising thymic cells or thymic epithelial cells as an active ingredient, and can prevent cancer by using thymic cells or thymic epithelial cells from childhood. The present invention can be helpfully utilized as a composition for preventing cancer in that thymic cells or thymic epithelial cells, which naturally degenerate after a certain period of time, can be used, and the extracted thymic cells or thymic epithelial cells can be easily treated through autograft.

Classes IPC  ?

• A61K 35/26 - LympheGanglions lymphatiquesThymusRateSplénocytesThymocytes
• A61P 35/00 - Agents anticancéreux

Abrégé

An RF catheter for treating hypertrophic cardiomyopathy includes: a body part constituting a catheter body made of a flexible and soft material; and an intraseptal insertion part provided at a distal part of the body part and having one or more electrodes, a tapered tip gradually becoming thinner toward an end thereof, and a guidewire lumen therein, into which a guidewire is inserted, so that during hypertrophic cardiomyopathy treatment, the intraseptal insertion part is inserted into the interventricular septum along the guidewire. A method of treating hypertrophic cardiomyopathy by using an RF ablation catheter includes: i) positioning the guidewire to a hypertrophied septum through a coronary sinus and a septal vein; ii) transferring the RF ablation catheter to the hypertrophied septum; and iii) performing RF ablation by applying RF energy to the electrodes provided at an end part of the RF ablation catheter by using an RF generator.

Classes IPC  ?

• A61B 18/14 - Sondes ou électrodes à cet effet
• A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci

Abrégé

Disclosed are a CT image processing method and a CT image processing apparatus for detecting and segmenting a perforator in a CT image. The CT image processing method may comprise the steps of: detecting, from a CT image, a region of interest (ROI) expected to have a perforator, by using an ROI detection model; generating a plurality of three-dimensional patches including at least a portion of the detected ROI; and inputting the plurality of three-dimensional patches to a perforator detection model and generating a result image obtained by extracting the perforator from the CT image on the basis of a segmentation result from the perforator detection model.

Classes IPC  ?

• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
• A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
• A61B 6/03 - Tomographie informatisée
• G06T 7/11 - Découpage basé sur les zones

Abrégé

The present disclosure relates to a haptic interface device for a remote vascular intervention procedure, comprising: a tube; a plurality of segments concentrically coupled with the tube; an opening formed on the periphery of the plurality of segments such that a user can move a main body by using his/her finger; an encoder for outputting an electrical signal by sensing at least one of a change in position, a direction, and an angle of the plurality of segments; a first motor unit configured in conjunction with the encoder and outputting feedback corresponding to the movement of the plurality of segments; a second motor unit for outputting feedback corresponding to the movement of the plurality of segments; and a processor for outputting a control signal for controlling the first motor, the second motor, and a slave robot, thereby operating the slave robot that moves a surgical tool in response to displacement data sensed by the encoder.

Classes IPC  ?

• A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
• A61B 34/35 - Robots chirurgicaux pour la téléchirurgie
• A61B 34/37 - Robots meneurs-suiveurs

Abrégé

An artificial structure for preventing or treating lymphedema and a construction method therefor. The artificial structure includes a first sheet and a second sheet arranged on the first sheet and including at least two channels. Each channel includes an inlet, an outlet, a one-way channel structure configured to maintain a one-way flow of lymph from the inlet toward the outlet, and a pattern on a surface facing the first sheet. The artificial structure is configured to maintain a normal flow of lymph despite the effects of lymphadenectomy and radiation exposure. The artificial structure has the effect of not only preventing the onset of lymphedema but also effectively being useful for treating diseases caused by interruption of lymph flow.

Classes IPC  ?

• A61M 27/00 - Appareillage pour drainage des blessures

Abrégé

A vascular therapy recommendation apparatus according to an embodiment may comprise: a processor that selects a target vascular image including a target blood vessel from among medical images obtained by photographing the target blood vessel in a plurality of directions, on the basis of a result of applying a first machine learning model to the medical images, selects a representative frame image including the target blood vessel from among a plurality of frame images included in the selected target vascular image, on the basis of a result of applying a second machine learning model to the plurality of frame images, generates input data including time series information by stacking the selected representative frame image, a previous frame of the representative frame image, and a subsequent frame of the representative frame image in order of photographing time, and recommends treatment guide information for the target blood vessel among pieces of candidate treatment guide information by applying a third machine learning model to the stacked input data; and a display for outputting the treatment guide information.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G06N 20/00 - Apprentissage automatique
• G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
• A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
• G06V 20/40 - ScènesÉléments spécifiques à la scène dans le contenu vidéo

Abrégé

The present invention relates to a stem cell therapeutic agent for preventing or treating temporomandibular joint diseases, and a production method therefor. Specifically, stem cells overexpressing at least one gene selected from the group consisting of IDO, TSG -6, and FGF2 are included as an active ingredient. When used, the agent can prevent cartilage loss in the temporomandibular joint and promote bone regeneration, and thus can be advantageously used for the fundamental prevention and treatment of temporomandibular arthritis.

Classes IPC  ?

• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• C12N 5/0789 - Cellules souchesCellules progénitrices multipotentes
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed are an apparatus and a method for predicting a bed occupancy rate in a hospital. The method for predicting a bed occupancy rate, performed by the apparatus for predicting a bed occupancy rate, according to an embodiment, may comprise the steps of: periodically collecting bed information data including information indicating whether a patient occupies each bed and hospital room identification information indicating a corresponding bed; generating, from the collected bed information data, ward data based on patient occupancy information dependent on the time in a ward including each bed; generating, from the collected bed information data, hospital room data based on at least one of patient occupancy information dependent on the time in a hospital room including each bed or time-independent hospital room identification information; training a machine learning-based occupancy rate prediction model by using training data generated on the basis of dividing at least one of the ward data and time-dependent information among the hospital room data into units of predetermined time periods; and applying the trained machine learning-based occupancy rate prediction model to input bed information data, so as to output occupancy rate information for at least one of a ward or a hospital room.

Classes IPC  ?

• G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• G06N 20/00 - Apprentissage automatique

Abrégé

The present invention relates to a composition for enhancing the anticancer effect of sorafenib, comprising a SASH1 overexpression vector as an active ingredient. The composition comprises a polynucleotide sequence for inducing the overexpression of SASH1 (SAM and SH3 domain-containing protein 1) comprising a sequence commonly expressed by isoforms of a SASH1 gene. Since the vector of the present invention has an excellent anticancer effect by itself while increasing the anticancer effect of sorafenib, the composition comprising the SASH1 overexpression vector and/or sorafenib as an active ingredient can be usefully used as a substance for preventing or treating cancer.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to: a biomarker composition comprising AMPD3 for predicting sensitivity to a therapeutic agent for neurofibromatosis (NF1); a pharmaceutical composition comprising an AMPD3 inhibitor for preventing or treating NF1; and use thereof. The composition according to one aspect is highly useful as a diagnostic marker for therapeutic agent sensitivity in patients with NF1, and can be used as a new therapeutic target for NF1.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61K 31/4245 - Oxadiazoles

Abrégé

The present invention relates to an injection control device and an operating method thereof. The injection control device according to one embodiment may comprise: a body to which a linear body including an injection needle connected to a tube integrating outlets of a plurality of cylinders is rotatably connected; a controller for receiving, from a user, a control manipulation instructing at least one of an operation for relative movement between a subject and the body, an operation for rotation of the linear body with respect to the body, or an operation for forward movement of the injection needle; and a processor for controlling the operation of at least one of the body, the linear body, or the injection needle on the basis of the control manipulation input through the controller.

Classes IPC  ?

• A61M 5/42 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour insensibiliser la peau, pour soulever la peau en vue de faciliter la piqûre ou pour localiser le point du corps où la piqûre doit être effectuée
• A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
• A61M 5/48 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour faire varier, pour réguler, pour indiquer ou pour limiter la pression d'injection
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61M 19/00 - Dispositifs pour l'anesthésie localeDispositifs pour l'hypothermie
• A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
• A61M 5/158 - Aiguilles

Abrégé

The present invention demonstrates the functional enhancement of melatonin-primed stem cells through ten indicators including self-renewal ability, engraftment rate, anti-inflammatory ability, and immunosuppressive ability in a cell culture model. It has been identified that in the primed stem cells according to the present invention, the activity of glutathione (GSH) is increased, through signaling involving cyclic adenosine monophosphate (cAMP) response element-binding protein-1 (CREB1) and nuclear factor (erythroid-derived-2) like-2 (NRF2) as a molecular mechanism and, simultaneously, the expression of PD-L1 protein is increased by JAK1-STAT3 signaling. The stem cells primed according to the present invention have improved stemness, and thus can be effectively used in the treatment of inflammatory diseases, immune diseases and the like.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to: a pharmaceutical composition for preventing or treating retinitis pigmentosa comprising an agent for inducing a deletion of an IMPDH1 C.947G > C (p.ARG316PRO) mutation, and a method for preventing or treating retinitis pigmentosa, comprising a step of inducing the deletion of the mutation; a composition for diagnosing or predicting retinitis pigmentosa, comprising an agent for detecting an IMPDH1 C.947G > C (p.ARG316PRO) mutation; and a method for providing information for diagnosing or predicting retinitis pigmentosa, comprising a step of detecting the mutation.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/22 - Ribonucléases
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 27/02 - Agents ophtalmiques

Abrégé

An embodiment of the present invention provides an automated angiography system comprising: a catheter unit including a catheter and a connector coupled to the catheter and through which a guidewire passes; a contrast medium injection unit for injecting a contrast medium into the catheter unit; a driving unit for controlling movements of the catheter and the guidewire; an image information acquisition unit for acquiring image information about a region of interest into which the contrast medium is injected; and a control unit for controlling the driving unit to control the movements of the catheter or the guidewire by using the image information or controlling the contrast medium injection unit to adjust an injection speed and the amount of the contrast medium.

Classes IPC  ?

• A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
• A61M 25/09 - Fils de guidage
• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61M 25/00 - CathétersSondes creuses
• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
• A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes

Abrégé

According to an aspect, a pharmaceutical composition for the prevention or treatment of an intraretinal angiogenic disease, which contains vascular endothelial cells exhibiting reduced expression or activity of beta-2 microglobulin (B2M) and increased expression or activity of tyrosine kinase receptor 2 (Tie2) compared to parent cells, as an active ingredient, induces stabilization of vascular endothelial cells and reduces vascular permeability even in a state of inflammation or over-expression of vascular endothelial growth factors (VEGF), so as to slow down or inhibit intraretinal angiogenesis, thereby preventing or treating an intraretinal angiogenic disease. In addition, since the cells of the present invention survives for a long period due to low immunogenicity, the effect of inhibiting angiogenesis lasts for a long period after a single intraocular injection, and thus the present invention allows the treatment to proceed less invasively compared to conventional antibody therapies, enhances vascular stability, and enables early diagnosis and treatment of an intraretinal angiogenic disease.

Classes IPC  ?

• A61K 35/44 - VaisseauxCellules de muscles vasculaires lissesCellules endothélialesCellules progénitrices endothéliales
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention relates to a composition for diagnosing or predicting the prognosis of solid cancer (for example, lung cancer). In the present invention, association between the onset of solid cancer and an increase in the expression level of USE1 is identified, and an aptamer sequence capable of detecting USE1 with high specificity is provided. If the aptamer of the present invention is used, solid cancer can be rapidly and simply diagnosed in a non-invasive manner by detecting USE1 with high specificity.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

A biomarker composition for predicting susceptibility to a therapeutic agent for neurofibromatosis by using Ras activity; and a pharmaceutical composition for preventing or treating neurofibromatosis, including a Ras activity inhibitor. The biomarker composition can accurately diagnose susceptibility to a therapeutic agent for neurofibromatosis by measuring the expression levels of a GTP-bound and activated Ras (Ras-GTP) protein and an activated p-ERK protein or a gene encoding the same in a biological sample of an individual. The pharmaceutical composition inhibits the activity of Ras proteins, and thus can be effectively used for the prevention or treatment of neurofibromatosis in which the activity of the Ras proteins is increased.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61K 31/4245 - Oxadiazoles
• A61P 35/00 - Agents anticancéreux
• C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides